Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety study of defibrotide (DF) for the prophylaxis of venoocclusive disease (VOD).

Trial Profile

Efficacy and safety study of defibrotide (DF) for the prophylaxis of venoocclusive disease (VOD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Veno-occlusive disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Aug 2016 Status changed from recruiting to completed.
    • 30 Mar 2016 According to a media release, the US FDA has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT).
    • 28 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top